Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

BACKGROUND: Anti-PD-1 and PD-L1 (collectively PD-[L]1) therapies are approved for many advanced solid tumors. Biomarkers beyond PD-L1 immunohistochemistry, microsatellite instability, and tumor mutation burden (TMB) may improve benefit prediction. METHODS: Using treatment data and genomic and transc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomlins, Scott A., Khazanov, Nickolay A., Bulen, Benjamin J., Hovelson, Daniel H., Shreve, Melissa J., Lamb, Laura E., Matrana, Marc R., Burkard, Mark E., Yang, Eddy Shih-Hsin, Edenfield, William Jeffery, Dees, E. Claire, Onitilo, Adedayo A., Thompson, Michael, Buchschacher, Gary L., Miller, Alan M., Menter, Alexander, Parsons, Benjamin, Wassenaar, Timothy, Hwang, Leon C., Suga, J. Marie, Siegel, Robert, Irvin, William, Nair, Suresh, Slim, Jennifer N., Misleh, Jamal, Khatri, Jamil, Masters, Gregory, Thomas, Sachdev, Safa, Malek, Anderson, Daniel M., Kwiatkowski, Kat, Mitchell, Khalis, Hu-Seliger, Tina, Drewery, Stephanie, Fischer, Andrew, Plouffe, Komal, Czuprenski, Eric, Hipp, Jennifer, Reeder, Travis, Vakil, Hana, Johnson, D. Bryan, Rhodes, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905474/
https://www.ncbi.nlm.nih.gov/pubmed/36750617
http://dx.doi.org/10.1038/s43856-023-00243-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905474/
https://www.ncbi.nlm.nih.gov/pubmed/36750617
http://dx.doi.org/10.1038/s43856-023-00243-7

Ejemplares similares